Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7443173 | 0.98 | SIGMAR1 (0.33) | SIGMAR1CACNA2D1 | |
| SCHEMBL17599756 | 0.88 | — | — | |
| SCHEMBL9415890 | 0.81 | SIGMAR1 (0.34) | SIGMAR1CACNA2D1 | |
| SCHEMBL551460 | 0.80 | ALDH1A1 (0.35) | — | |
| Carbimide SCHEMBL27427109 | 0.78 | HTR2A (0.33) | — | |
| Water SCHEMBL28125507 | 0.78 | HTR2A (0.33) | — | |
| Hydrochloric Acid SCHEMBL58713 | 0.78 | HTR2A (0.33) | — | |
| Water SCHEMBL27976893 | 0.78 | HTR2A (0.33) | — | |
| SCHEMBL27759471 | 0.78 | HTR2A (0.33) | — | |
| SCHEMBL13847959 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | disclosed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | disclosed |
| US-6464971-B1 | ANIONIC-CONTAINING MOIETY IS A NEURAMINIC- OR SIALIC ACID-CONTAINING. MOIETY, IT IS MODIFIED IN THE 4-POSITION BY SUBSTITUTION WITH AN AMINO, AMIDO, CYANO, AZIDO OR GUANIDO GROUP, OR IS UNSATURATED. | STARPHARMA LIMITED (AU) | 2002-10-15 | — | — | US | disclosed |
| US-5374643-A | Aryl urea (thiourea) and cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | SIGMAR1 1742/4885CACNA2D1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.